PCVX Vaxcyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCVX

Price (delayed)

$66.47

Market cap

$7.21B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.14

Enterprise value

$6.84B

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious ...

Highlights
Vaxcyte's equity has increased by 30% YoY but it has decreased by 12% QoQ
The debt has surged by 112% since the previous quarter and by 63% year-on-year
The net income has plunged by 80% YoY and by 34% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://vaxcyte.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of PCVX
Market
Shares outstanding
108.41M
Market cap
$7.21B
Enterprise value
$6.84B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.1
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$402.27M
EBITDA
-$392.1M
Free cash flow
-$364.67M
Per share
EPS
-$4.14
Free cash flow per share
-$3.75
Book value per share
$13.04
Revenue per share
$0
TBVPS
$14.49
Balance sheet
Total assets
$1.41B
Total liabilities
$167.45M
Debt
$29.22M
Equity
$1.24B
Working capital
$950.62M
Liquidity
Debt to equity
0.02
Current ratio
7.54
Quick ratio
7.43
Net debt/EBITDA
0.94
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-29.7%
Return on equity
-32%
Return on invested capital
-48.9%
Return on capital employed
-31.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCVX stock price

How has the Vaxcyte stock price performed over time
Intraday
2.97%
1 week
9.47%
1 month
2.1%
1 year
34.31%
YTD
5.84%
QTD
-2.69%

Financial performance

How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$468.04M
Net income
-$402.27M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has shrunk by 102% YoY and by 31% QoQ
The net income has plunged by 80% YoY and by 34% from the previous quarter

Growth

What is Vaxcyte's growth rate over time

Valuation

What is Vaxcyte stock price valuation
P/E
N/A
P/B
5.1
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 24% from the previous quarter and by 20% YoY
The P/B is 34% higher than the last 4 quarters average of 3.7
Vaxcyte's equity has increased by 30% YoY but it has decreased by 12% QoQ

Efficiency

How efficient is Vaxcyte business performance
PCVX's ROIC has soared by 66% year-on-year but it is down by 4% since the previous quarter
Vaxcyte's return on equity has increased by 27% YoY but it has decreased by 26% QoQ
PCVX's ROA is up by 26% YoY but it is down by 24% QoQ

Dividends

What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCVX.

Financial health

How did Vaxcyte financials performed over time
The total liabilities has surged by 79% since the previous quarter
Vaxcyte's current ratio has shrunk by 68% YoY and by 50% QoQ
The debt is 98% smaller than the equity
The debt has surged by 112% since the previous quarter and by 63% year-on-year
The company's debt to equity has surged by 100% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.